BAM Logo

Biotherapy : Adalimumab

[Biothérapie : Adalimumab]

EPTIS factsheet 587040 | Last revision 2019-06-17 | URL: https://www.eptis.bam.de/pts587040 https://www.eptis.bam.de/pts587040

PT provider
PT provider CTCB CTCB
Based in France
Language(s) English /French
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Quantification of drug serum concentrations human serum all methods
Anti-adalimumab antibodies detection and quantification human serum all methods
Aims of the PT scheme
Target group of participants merdical laboratories / no restriction to participation but possible extra charges according to the country
Linked to specific legislation / standards no
Additional, subsidiary aims
Number of participants 23
Accredited or otherwise reviewed by a 3rd party

Accredited by no on the basis of


Operation is commissioned / requested by no
Fees and frequency
Participation fee 428 euros
Regularly operated Yes (3 times a year (1 sample per survey))
Year of first operation 2018
Contact details of the PT provider
Provider Contact person
33 route de Bayonne

Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Web: https://www.ctcb.com/ https://www.ctcb.com/
Mrs Stéphanie Albarede
Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Email: s.albarede@ctcb.com s.albarede@ctcb.com
If you find any mistakes please contact the responsible EPTIS coordinator in France, Mr Patrick Bironneau. Mr Patrick Bironneau.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21